Brief: Cullinan Oncology Significantly Increases Ownership Stake In Its MICA Subsidiary Which Holds Worldwide Rights To Clinical-Stage Novel Monoclonal Antibody CLN-619

Cullinan Therapeutics

25/10/2022 12:32

Oct 25 (Reuters) - Cullinan Oncology Inc  CGEM.O :
    * CULLINAN ONCOLOGY SIGNIFICANTLY INCREASES OWNERSHIP STAKE
IN ITS
MICA SUBSIDIARY WHICH HOLDS WORLDWIDE RIGHTS TO CLINICAL-STAGE
NOVEL MONOCLONAL ANTIBODY CLN-619
    * CULLINAN ONCOLOGY INC - ONGOING PHASE I CLINICAL TRIAL FOR
CLN-619 REMAINS ON TRACK TO REPORT INITIAL CLINICAL DATA IN
MID-2023
    * CULLINAN ONCOLOGY INC - CULLINAN INCREASES OWNERSHIP IN
MICA
SUBSIDIARY FROM 54% TO 92% THROUGH SHARE PURCHASE FROM EXISTING
FINANCIAL INVESTORS

Source text for Eikon:  ID:nGNX5y2CRV 
Further company coverage:  CGEM.O 
 ((Reuters.Briefs@thomsonreuters.com;;))